Hugging Face's logo

Datasets:
nzindoc
/
dataset-multiple-myeloma-study-dictionary

Tags:
Dataset card Viewer Files Community
Dataset Viewer
Auto-converted to Parquet
Viewer
instruction
stringclasses
1 value
input
stringlengths
104
436
output
stringlengths
45
55
text
stringlengths
247
577
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
End of preview. Expand in Dataset Viewer.

Dataset Card for "dataset-multiple-myeloma-study-dictionary"

More Information needed

Downloads last month
0
Edit dataset card
Size of downloaded dataset files:
30.4 MB
Size of the auto-converted Parquet files:
30.4 MB
Number of rows:
1,975,680